Inovio announced positive results from early-stage testing of its experimental Covid-19 vaccine Tuesday and said it has been selected to participate in the federal government’s “Operation Warp Speed” program that is seeking to have a vaccine available by year’s end.

The Plymouth Meeting biotechnology company said 94% of the phase-I trial participants demonstrated overall immune responses at Week 6 after two doses of vaccine candidate INO-4800, according to a preliminary analysis of the study data.…